King's College London-ko ikertzaileekin lankidetzan egindako argitalpenak (51)

2025

  1. A network approach exploring the effects of cognitive remediation on cognition, symptoms, and functioning in early psychosis

    Psychological Medicine, Vol. 55

  2. Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

    Schizophrenia Bulletin Open, Vol. 6, Núm. 1

  3. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  4. Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program

    Schizophrenia Bulletin Open, Vol. 6, Núm. 1

  5. Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  6. The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  7. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

    Schizophrenia, Vol. 11, Núm. 1

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Cognitive remediation therapy to enhance cognition and improve recovery in early psychosis: the ECLIPSE research programme including an RCT

    Programme Grants for Applied Research, Vol. 12, Núm. 4

  3. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  4. Effects of cannabidiol on symptoms in people at clinical high risk for psychosis

    World Psychiatry

  5. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

    Psychological Medicine, Vol. 54, Núm. 5, pp. 993-1003

  6. Understanding the Mechanisms of Cognitive Remediation on Recovery in People With Early Psychosis: A Mediation and Moderation Analysis

    Schizophrenia bulletin, Vol. 50, Núm. 6, pp. 1371-1381

2023

  1. Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode Participants

    Schizophrenia bulletin, Vol. 49, Núm. 3, pp. 614-625

  2. Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  3. Predicting treatment resistance from first-episode psychosis using routinely collected clinical information

    Nature Mental Health, Vol. 1, Núm. 1, pp. 25-35

  4. Satisfaction with cognitive remediation therapy: its effects on implementation and outcomes using the cognitive remediation satisfaction scale

    Schizophrenia, Vol. 9, Núm. 1

  5. What interventions should we implement in England's mental health services? The mental health implementation network (MHIN) mixed-methods approach to rapid prioritisation

    Frontiers in Health Services, Vol. 3

2022

  1. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, Núm. 3, pp. 461-475

  2. Determinants of patient-reported outcome trajectories and symptomatic recovery in Improving Access to Psychological Therapies (IAPT) services

    Psychological Medicine, Vol. 52, Núm. 14, pp. 3231-3240